Onconetix (ONCO) Other Non-Current Liabilities (2022 - 2026)
Onconetix (ONCO) posted quarterly Other Non-Current Liabilities of $24978.0 for Q1 2026, down 52.77% year-over-year from $52884.0 in Q1 2025, and down 99.45% quarter-over-quarter from $4.6 million in Q4 2025.
Onconetix (ONCO) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Other Non-Current Liabilities for 5 consecutive years, with $24978.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 52.77% year-over-year to $24978.0; the TTM figure through Mar 2026 stood at $24978.0 (down 52.77% YoY), while the FY2025 annual figure was $4.6 million, up 9.97% from the prior year.
- Other Non-Current Liabilities eased to $24978.0 in Q1 2026 per ONCO's latest filing, from $4.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $13.8 million in Q3 2025 and bottomed at $2641.0 in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $2.1 million across 5 years, with a median of $42056.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities slumped 93.23% — and 2024, when it soared 157646.65%.
- Onconetix's Other Non-Current Liabilities stood at $39000.0 in 2022, then plunged by 93.23% to $2641.0 in 2023, then jumped by 157646.65% to $4.2 million in 2024, then gained by 9.97% to $4.6 million in 2025, then plunged by 99.45% to $24978.0 in 2026.
- Business Quant data shows ONCO's Other Non-Current Liabilities at $24978.0 in Q1 2026, $4.6 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 674,512.00 |
| Mar 31, 2026 | 24,978.00 |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 13.80 Mn |
| Jun 30, 2025 | 53,113.00 |
| Mar 31, 2025 | 52,884.00 |
| Dec 31, 2024 | 4.17 Mn |
| Sep 30, 2024 | 26,000.00 |
| Dec 31, 2023 | 2,641.00 |
| Dec 31, 2022 | 39,000.00 |
| Sep 30, 2022 | 42,056.00 |
| Jun 30, 2022 | 5,373.00 |